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Cinnamon extract is associated to different health benefits but the active ingredients or pathways are
unknown. Cinnamaldehyde (CIN) imparts the characteristic flavor to cinnamon and is known to be the
main agonist of transient receptor potential-ankyrin receptor 1 (TRPA1). Here, expression of TRPA1 in
epithelial mouse stomach cells is described. After receiving a single-dose of CIN, mice significantly reduce
cumulative food intake and gastric emptying rates. Co-localization of TRPA1 and ghrelin in
enteroendocrine cells of the duodenum is observed both in vivo and in the MGN3-1 cell line, a ghrelin
secreting cell model, where incubation with CIN up-regulates expression of TRPA1 and Insulin receptor
genes. Ghrelin secreted in the culture medium was quantified following CIN stimulation and we observe
that octanoyl and total ghrelin are significantly lower than in control conditions. Additionally, obese mice
fed for five weeks with CIN-containing diet significantly reduce their cumulative body weight gain and
improve glucose tolerance without detectable modification of insulin secretion. Finally, in adipose tissue
up-regulation of genes related to fatty acid oxidation was observed. Taken together, the results confirm
anti-hyperglycemic and anti-obesity effects of CIN opening a new approach to investigate how certain spice
derived compounds regulate endogenous ghrelin release for therapeutic intervention.
B
eyond the taste impact of spices, numerous health benefits have been ascribed to naturally derived flavoring
molecules. However, the molecular mechanisms by which these molecules mediate their effects remain
largely unknown.
Cinnamon is a spice used in cooking since biblical times. It is a brown powder obtained from the inner side of
the bark of different species of the genus Cinnamomun. 90% of the essential oil of the cinnamon bark is
Cinnamaldehyde (CIN), one of the active components of cinnamon that gives its typical flavor and odor.
Cinnamon extract has been linked to many different health benefits. There are numerous reports about the role
of cinnamon in obesity and diabetic conditions1–4. So far, there is neither consensus about the constituents of
cinnamon driving these effects nor the molecular pathways responsible for its benefits. CIN has been already
described to be responsible for the anti-diabetic5,6 and anti-obesity properties of cinnamon3,4.
CIN is also well-known as the principal agonist of TRPA1 (transient receptor potential-ankyrin receptor 1)7.
TRP channels are non-selective cation channels that participate in diverse sensory processes, including cold and
warm nociception, hearing, or inflammatory pain8–10. Besides CIN, several naturally occurring compounds
activate TRPA1 such as mustard, garlic, and horseradish, which produce a pungent sensation7,11. TRPA1 is
expressed in sensory neurons but recently has been shown to be expressed in the gastrointestinal tract as well
as inmany different epithelial cells in the intestine and also in the lungs12–14. TRPA1 expressed in the gut has been
described as a sensor molecule of enterochromaffin cells for the regulation of gastrointestinal functions14,15
through serotonin release.
Obesity is one of the greatest public health challenges of the 21st century. Its prevalence has tripled in many
countries of the European Region since the 1980s, and the number of people affected continues to rise at an
alarming rate. Excess weight drastically increases a person’s risk of developing a number of noncommunicable
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diseases, including cardiovascular disease, cancer and diabetes.Many
different spices are known for their use in traditional medicine and
positive effects in human health. Here the effect of CIN in glycemia
and weight management control is reported.
The physiological effects of cinnamaldehyde ingestion in the
gastrointestinal tract, caused by TRPA1 activation are: modifications
in gut motility14,16, gastric emptying15, cholecystokinin secretion in
the small intestine17 and serotonin release from intestinal entero-
chromaffin cells14. Very recently also the expression and role of
TRPA1 in insulin release from pancreatic b-cells has been
described18. In addition, CIN through TRPA1 activation can have
an effect on the metabolism as an enhancer of energy expenditure
through adrenaline secretion19 and autonomic thermoregulation20
Confirming this pathway, it has been also shown that CIN stimulates
interscapular brown adipose tissue, by an increase of thermogenin
(UCP1) protein, and visceral fat deposition in mice fed with high fat
and sucrose diet19,21.
This study aimed to investigate whether TRPA1-agonists affect
food intake and gastric emptying via ghrelin release. Ghrelin is an
orexigenic hormone produced predominantly in the stomach and
proximal small bowel. Ghrelin also acts as endogenous ligand for the
growth hormone secretagogue receptor and as a potent stimulator of
feeding22. Recently, ghrelin has been implicated in the regulation of
glucose homeostasis and insulin levels23,24. It has been suggested that
ghrelin antagonists could provide a potential therapeutic solution to
stop the progression of type 2 diabetes. The expression pattern and
gene expression of TRPA1 in stomach and small intestine were
determined. In vivo (acute and long-term treatment) and in vitro
evaluation of the CIN effect in the gut physiology and ghrelin secre-
tion respectively was performed.Moreover, the expression of TRPA1
in epithelial cells of the stomach and the enrichment of TRPA1
mRNA in the pyloric part of the stomach of mice have been shown.
The co-expression of TRPA1 and ghrelin in enteroendocrine cells
(EC) of the duodenum and the potential role and physiological rel-
evance of this receptor in ghrelin cells have been described. Finally,
after repeated ingestion of CIN, Diet induced Obese (DIO) mice
present a reduction of body weight gain as well as an improvement
of insulin sensitivity. The observed up-regulation of ACSL4 in brown
adipose tissue (BAT) and Cpt1a in white adipose tissue (WAT) could
indicate an increase of fatty acid oxidation and therefore a decrease of
fat mass. These results suggest that CIN could be used as a potential
anti-hyperglicemic and anti-obesity compound.
Results
TRPA1 and ghrelin expression in the gut. Using qRT-PCR (Fig. 1)
and in-situ hybridization (Fig. 2) techniques, the expression of
TRPA1 through the gastrointestinal tract has been confirmed and
described. The level of expression in the esophagus was undetectable.
In the stomach, we observed higher TRPA1 mRNA expression in the
inferior half of the stomach body (named ‘‘Pyloric’’, insert Fig. 1; light
grey portion), as opposed to the upper region (named ‘‘Cardia’’, insert
Fig. 1. dark grey portion). TRPA1 mRNA has been found along the
small and large intestine (Fig. 1). Furthermore, we observed that the
expression pattern of TRPA1 is similar and proportional to the ghrelin
expression pattern with higher expression in the pyloric part of the
stomach, lower in cardia and both of them decreased toward the lower
gastrointestinal tract (Fig. 1).
To determine which type of cells express TRPA1, a combination of
immunohistochemistry and in situ hybridization was performed
(Fig. 2). In the duodenum, by double staining with anti-chromogra-
nin A antibody (Chromogranin A; CgA) and a fluorescence labeled
anti-TRPA1 probe, the percentage of co-localization between
TRPA1 and CgA was identified. The last one marks all enteroendo-
crine cell types except CCK- andmotilin-expressing cells. 60% of the
CgA-positive cells express TRPA1 in the villi, however this percent-
age is higher (96%) in the crypts of the duodenum (Fig. 2A).
Furthermore, also by double staining with immunohistochemistry
(ghrelin) and in situ hybridization (TRPA1), we observed that ghre-
lin positive cells of the duodenum, scattered in the epithelia of crypts
and villi, displayed up to 65% co-localization with TRPA1 (Fig. 2B).
Fluorescence from the ghrelin vesicles was observed mainly in the
basal side of cells, while TRPA1 mRNA seemed to be distributed
across the whole cytoplasm of the cell or mainly in the apical part
of the cells.
Using in-situ hybridization, the precise localization of TRPA1
mRNA expressing cells in the stomach was shown (Fig. 2C). Most
of this mRNA appeared in the glandular base decreasing in amount
as the glands extend toward the lumenwith a few cells observed in the
glandular neck (Fig. 2 C1). The morphology of the positive cells was
small and round shaped (Fig. 2 C2 and C3). In situ hybridization
with DAB confirmed the localization of TRPA1 mainly in the crypts
of the duodenum (arrows) (Fig. 2D1 and D2). Finally, as a positive
control, we stained TRPA1 positive cells in trigeminal root ganglia,
(Fig. 2D3) with DAB.
Ghrelin secretion of the MGN3-1 cell line is reduced by
cinnamaldehyde. The MGN3-1 cell line (mouse ghrelinoma 3-1)
is a ghrelin-producing cell line derived from stomach25. We
confirmed co-localization of TRPA1 and ghrelin in these cells and
studied the effect of CIN, on gene expression and ghrelin secretion.
First, to confirm the expression of TRPA1 in MGN3-1 cells, the
relative amount of TRPA1 mRNA was measured by qRT-PCR,
which was similar to the one of ghrelinO-acyltransferase (GOAT)
responsible for adding an octanoyl group to pro-ghrelin at position
Ser-3. Second, to investigate the possible roles of TRPA1 inMGN3-1
cells, the effect of CIN on the expression of several genes (TRPA1,
Figure 1 | Distribution of ghrelin and TRPA1 mRNA assessed by qRT-PCR. Relative amount of Ghrelin (A) and TRPA1 (B) mRNA. Error bars
represents SEM. (n510).
www.nature.com/scientificreports
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Insulin receptor (InsR), Ghrelin and GOAT) was measured.
Addition of 100 mM CIN up-regulated the expression of two genes:
TRPA1 and InsR (Fig. 3A and B). Upregulation of InsR at the protein
level was also confirmed by Western Blot (Supplementary Fig. 1A).
No significant differences were found for Ghrelin and GOATmRNA
(see Fig. 3C and D).
Additionally, MGN 3-1 cells were used to study the effect of CIN
on ghrelin secretion. Active and total ghrelin secreted in the cell
culture medium 4 hours after stimulation with 100 mM of CIN were
measured and we observed that octanoyl ghrelin and total ghrelin
secreted were significantly lower (44%) than in control conditions.
When 25 mM of the TRPA1 inhibitor HC-030031 was added at the
same time than CIN to the cells, 12% of the effect of CIN on ghrelin
secretion was blocked and no effect was observed with HC-030031
alone (Fig. 4A). Total ghrelin secreted in the media was affected
exactly in the same manner than octanoyl ghrelin by CIN and HC-
030031 (Fig. 4B). By Western Blot analysis, the reduction of ghrelin
after CIN treatment has been confirmed (Supplementary Figure 1B),
suggesting with regards to the qRT-PCR results (Fig. 3C) that CIN
impacts ghrelin at a post-transcriptional level.
Acute administration of cinnamaldehyde reduces food intake (FI)
and gastric emptying. Since in vivo co-localization of ghrelin-
secreting cells and TRPA1 expression was found, and in vitro a
decrease of ghrelin secretion in MGN3-1 cells when stimulated
with CIN, we tested, first, if TRPA1 activation has any effect on FI
after an acute treatment with CIN. To this end, the impact of a single
dose of CIN on FI was measured. Mice received a gavage with
250 mg/kg (bw) of CIN and food intake was measured every two
hours during the subsequent 24 hours. Strong and significant
reduction of cumulative food intake was found 2 hours after the
treatment. In addition, we observed that 10 hours after the gavage,
mice treated with CIN, compensated the total amount of food
ingested reaching the same quantity as control mice (Fig. 5A).
Secondly, it was tested if CIN affects gastric emptying and intest-
inal transit. Mice were gavaged with a non-absorbable fluorogenic
Figure 2 | Tissue and cellular distribution of TRPA1 in gastrointestinal tract and other tissues. Fluorescent in situ hybridization and immune-
localization of TRPA 1 (green) and enteroendocrine cell marker Chromogranin A (CgA) (red), respectively (A1–A3). Note high co-localization of TRPA1
and Cg A in the cells located in the crypts of the duodenal mucosa; under the discontinuous line (A3). Many of the CgA positive cells localized in the villi
do not co-localize with TRPA1 (above the discontinuous line, arrows) (A3). Co-localization of ghrelin and TRPA1 in two cells located in two different
crypts of the duodenum (arrows) (B1–B3). In situ hybridization withDAB cross section of stomach in the pyloric region under lightmicroscope (C1-C3).
TRPA1 positive cells aremostly located in the glandular base of the stomach (C1).Highermagnification of TRPA1 expressing cells. Small and round shape
(C2–C3). In situ hybridization withDAB reveals localization of TRPA1 in the crypts of the duodenum (arrows) (D1) and the detailed shape of the positive
cells (D2). TRPA1 positive cells in trigeminal root ganglia, as a positive control (E1). Scale bars5 100 mm in (A1–A3); 20 mm in (B1–B3); 200 mm (C1);
5 mm (C2); 5 mm (C3); 50 mm (D1); 20 mm (D2); 50 mm (E1).
www.nature.com/scientificreports
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marker (FITC-dextran; MW 70,000) with or without 250 mg/kg bw
of CIN. No significant differences in the calculation of the geometric
center were observed in animals treated with or without CIN: 6.205
6 0.253 versus 6.325 6 0.259 (geometric center: mean segment
number 6 SEM). The gastric emptying rate however was signifi-
cantly slower in mice gavaged with CIN (Fig. 5B). Indeed, in mice
gavaged with CIN, 19.2% of the FITC-dextran remained in the stom-
ach in contrast to 4.6% in mice gavaged with control solution. To
verify the role of TRPA1 in the effect of CIN on gastric emptying the
same experiment was performed using TRPA1 (-/-) mice9 and the
proper control mice. In TRPA1 (-/-) mice the difference in gastric
emptying was not significant (Fig. 6).
Repeated ingestion of Cinnamaldehyde reduces body weight gain
in HFD-induced obese mice (DIO-mice). To better understand the
effect of CIN administrated in a chronic manner during 5 weeks,
daily FI and BW were measured in DIO-mice fed with high fat food
(60% of calories coming from fat) containing 0.2% of CIN. Contrary
to the acute treatment, daily food intake was not affected by CIN
(Fig. 7B) but surprisingly CIN had a significant impact reducing
cumulative bodyweight gain starting at day 24 of treatment (Fig. 7A).
Consistent with the reduced body weight, CIN-treated mice had
reduced body fat mass gain compared with controls (HFD: 5.2 g 6
0.3 g; HFD 1 0.2% CIN: 4.5 6 0.3 g; p-value: 0.06) (Table 1, NMR
results). However, no significant differences were observed in the
plasma cathecholamine levels. As a marker for liver injury the levels
of liver transaminases, have been measured, and no differences were
found between group control and CIN-treated mice (Table 1).
Moreover, we found no differences in plasma levels of creatinine,
cholesterol and triglycerides between themice treated with and with-
out CIN. Also for the plasma hormone levels of leptin and adipo-
nectine (Table 1). CIN did not affect lipid absorption in HFD-obese
mice. No significant differences in lipid content of the feces were
found between CIN and control treated.
Repeated ingestion of Cinnamaldehyde improves insulin
sensitivity in HFD-induced obese mice. To test whether the
ability to use glucose was changed after the treatment with CIN, an
Figure 3 | Regulation of gene expression by CIN in MGN3-1 cells. Cinnamaldehyde (100 mM) increases TRPA1 (A) and InsR (B) expression
significantly but does not affect Ghrelin (C) or GOAT (D) expression. (*; p,0.05, n54 error bars: SEM).
Figure 4 | Regulation of ghrelin secretion by CIN in MGN 3-1 cells. Four hours treatment of MGN 3-1 cells with CIN (100 mM) decreases both
octanoyl ghrelin (A) and total ghrelin (B) secreted in themedium. This effect is partially recovered by the inhibition of TRPA1 with HC-030031 (25 mM).
No effect is observed on the secretion of ghrelin when the inhibitor is applied alone (A and B). (*, p,0.05; **, p,0.01*; ***, p,0.005 n53; error bars:
SEM).
www.nature.com/scientificreports
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oral glucose tolerance test (OGTT) was performed in fasting
conditions during the last week of the chronic treatment. Mice
treated with CIN showed statistically significant decrease of blood
glucose levels after a glucose load. These mice showed already a
reduction of 10.6% of blood glucose levels in fasting conditions
compared to the control group. During the OGTT, CIN treated
mice showed a reduction of 21%, 29.8%, 25% and 8.25% of blood
glucose levels after 159, 309, 609 and 1209 respectively after the
ingestion of glucose (Fig. 8). However, plasma insulin levels in the
fasting state (Table 1) and during the OGTT (data not shown) were
unchanged by the CIN treatment.
This improvement in glucose tolerance without a change in the
plasma insulin concentration suggests enhanced sensitivity to insulin
in the periphery in response to a glucose load following treatment
with CIN.
Effect of repeated ingestion of Cinnamaldehyde on gene expres-
sion related to fat metabolism and glucose transport of HFD-
induced obese mice. From the different tissue samples collected at
the end of the chronic treatment, gene expression analysis was
performed to measure the relative mRNA amount of different sets
of genes in each specific tissue (supplementary data).
Brown adipose tissue (BAT):After CIN treatment, a significant up-
regulation of enzyme acyl-CoA synthetase 4 (ACSL4) was found
(Table 2). This enzyme acitvates fatty acids destined for b-oxidation.
Other genes were measured (see supplementary data) but no signifi-
cant differences were found.
White adipose tissue (WAT): Up-regulation of several glucose trans-
porters GLUT1, GLUT12, and GLUT 8, Cpt1a involved in stimulation
of fatty acid oxidation and insulin receptor has been observed after CIN
treatment compared to the control group (Table 2).
Figure 5 | Effect on short term food intake and gastric emptying of mice receiving a CIN gavage. Mice, after overnight fasting, received a single
gavage of CIN (250 mg/kg bw) or an equivalent volume of water for control animals. Subsequently, either food intake (A) or intestinal transit was
measured (B). A: CIN reduces significantly cumulative food intake during the 2 hours after the gavage, compared to the control group. (*, p,0.05; n525)
B: CIN does not affect the intestinal transit time: geometric center being 6.21 6 0.25 for the CIN group and 6.32 6 0.26 for the control group. However,
gastric emptying is slowed with CIN compared to the control group, in stomach and the two first segments of the intestine there is significantly more
fluorescent dye in CIN group, SI: small intestine (*, p,0.05; **, p,0.01*; ***, p,0.005; n56; error bars: SEM).
Figure 6 | Effect of CIN gavage on gastric emptying of TRPA1 (-/-) mice.After a overnight fasting,WT and TRPA1 (-/-) animals received a single gavage
of CIN (250 mg/kg bw) or an equivalent volume of water containing a fluorescent tracer. One hour after the gavage the presence of the dye in the stomach
was measured. There was no significant difference in the content of dye in the stomach of TRPA1(-/-) animals gavaged or not with CIN, whereas we
observed an increase of the presence of dye inWT animals gavagedwith CIN compared to those gavagedwith water. (*, p,0.05; n.s., not significant; n56;
error bars: SEM).
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 5 : 7919 | DOI: 10.1038/srep07919 5
Muscle: No difference was found for any of the following genes:
GLUT1; GLUT4; GLUT8; GLUT10; GLUT11; GLUT12; IL-6; MCP-
1; insulin receptor; very low expression for GLUT5 and no express-
ion of TRPA1 and SGLT3.
Liver: No difference was found for any of the genes analyzed
(GLUT1; GLUT10; GLUT2; GLUT9; very low expression for IL-6
and no expression for SGLT3 and TRPA1).
Discussion
Over many years cinnamon has been described and used in tra-
ditional medicine to moderate postprandial glycemia and positively
change body composition, although little was known about the
mechanism of action for this spice26–28. The results obtained here
contribute to clarify which are the active molecules and potential
pathways responsible for these effects. Our results demonstrate, that
ghrelin and TRPA1 co-localize in the same EC of the duodenum and
that CIN decreases ghrelin secretion partially via TRPA1 activation.
Ghrelin is a potent orexigenic peptide that stimulates food intake
and bodyweight gain, indicating that this hormone plays an import-
ant role in energy homeostasis. Moreover, recently several studies
have demonstrated that gluconeogenesis and glycogenolysis are
increased and insulin sensitivity is improved by the ablation of the
ghrelin or growth hormone secretagogue receptor in mice29 and that
ghrelin suppresses glucose-induced insulin release and that it dete-
riorates glucose tolerance23,24. Therefore, ghrelin antagonists are
promising targets for pharmacological intervention in the treatment
of obesity and type 2 diabetes.
MGN3-1 cells represent an ideal in vitro tool to study the potential
effects of different ingredients on ghrelin secretion. Iwakura et al.25
demonstrate that ghrelin secretion is suppressed by somatostatin and
insulin, indicating that MGN3-1 cells preserve the intrinsic charac-
teristics of ghrelin-producing cells. The level of TRPA1 expression in
these cells is considerably high, with the same relative amount of
expression as GOAT enzyme. This could support the importance
of this channel in ghrelin secreting cells.
The fact that TRPA1 activation (with CIN) decreases ghrelin
secretion and up-regulates insulin receptors (in vitro), supports that
CINworks as anti-hyperglycemic drug and, potentially, as an enhan-
cer of insulin sensitivity through regulation of ghrelin secretion. We
could not block 100% of the CIN effect in MGN3-1 cells, so we
hypothesize about the existence of a different receptor activated by
CIN or the poor efficiency of HC-030031 in this specific cell type.
Figure 7 | Effect of chronic intake of 0.2% CIN included in the diet of obese mice on daily food intake and body weight gain. 0.2% of CIN was included
in the high fat diet of DIO mice for a period of 5 weeks and body weight gain and food intake was measured daily. We did not observe any effect on
food intake, whereas a significant effect on cumulative body weight gain was observed from day 24. (*, p,0.05; n533; error bars: SEM).
Table 1 | Summary of measured parameters in mice treated (HFD 1 0,2% CIN) or not (HFD) with CIN for 5 weeks
HFD HFD 1 0,2% CIN T-test p-value N
Fat mass gain [g] 5.2 6 0.3 4.5 6 0.3 0.06 33
Lean mass gain [g] 1.9 6 0.2 0.5 6 0.1 0.1 33
Fasting plasma glucose [mmol/L] 8.42 6 0.30 7.54 6 0.25 0.03 12
Fasting plasma insulin [ng/mL] 4.73 6 0.39 4.77 6 0.31 0.94 12
Dopamine [pg/mL] 118.6 6 30.4 88.2 6 13.5 0.37 10
Adrenaline [pg/mL] 479.7 6 66.1 456.3 6 63.7 0.8 10
Noradrenaline [pg/mL] 1851.4 6 485.2 1465.6 6 121.2 0.45 10
iBAT temperature [uC] 30.47 6 0.25 30.20 6 0.41 0.58 10
Liver weight/body weight [%] 3.91 6 0.26 3.76 6 0.26 0.68 10
iBAT weight/body weight [%] 0.75 6 0.06 0.69 6 0.03 0.35 10
Plasma ASAT [U/L] 94.30 6 9.19 81.49 6 6.02 0.61 10
Plasma ALAT [U/L] 87.94 6 12.17 74.04 6 10.95 0.59 10
Plasma creatinine [mmol/L] 5.15 6 0.48 5.73 6 0.63 0.12 10
Plasma total cholesterol [mmol/L] 4.72 6 0.29 4.78 6 0.33 0.89 10
Plasma triglyceride [mmol/L] 0.69 6 0.05 0.67 6 0.03 0.69 10
Plasma FFA [mmol/L] 0.47 6 0.03 0.49 6 0.03 0.47 10
Calorie content in 24 h faeces 3516.96 6 21.27 3549.40 6 29.42 0.38 15
Plasma adiponectine [ng/mL] 9.29 6 0.48 8.75 6 0.54 0.47 10
Plasma leptine [ng/mL] 68.10 6 6.40 66.90 6 5.96 0.89 10
www.nature.com/scientificreports
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Our in vivo experiments also provide data supporting the effect of
CIN on ghrelin secretion. After long-term treatment with HFD 1
0.2% CIN, glucose plasma levels decrease significantly in fasting
conditions and during OGTT, whereas insulin levels are similar. In
fact, CIN demonstrates to have the same effect as the already
described effect of insulin decreasing ghrelin secretion30,31.
Improved oral glucose tolerance values normally are the result of
two phenomena, either enhanced peripheral tissue (muscle and adip-
ose tissues) sensitivity to insulin or an improvement in hepatic insu-
lin sensitivity. Our RT-PCR results show, after 36 days feeding HFD
supplemented with 0.2%CIN, an up-regulation of 3 different glucose
transporters (GLUT1, 8 and 12) and InsR in WAT. However, it still
remains to be demonstrated if the observed improvement of insulin
sensitivity is a cause or a consequence of this up-regulation.
TRPA1 has been detected in rat pancreatic b-cells18. Using in vitro
assays, it was observed that TRPA1 ligands induce basal insulin
release by Ca21 influx. This path could also participate to the overall
enhanced glucose tolerance, although in this study we do not observe
any changes in insulin plasma levels.
Taken together, all these observations indicate that CIN has a
strong potential as an anti-hyperglycemic drug to be used in diabetes
type 2 treatment.
In addition, a significant delay in gastric emptying is observed after
a single gavage of CIN in mice (Fig. 5B) but we do not observe any
increase of the motility along the rest of the gastrointestinal tract as it
has been shown in dogs and isolated guinea pig ileum14,16. The geo-
metric center of the dye distribution in the gut was calculated as well,
and no difference is found between treated and untreated mice. This
delay of gastric emptying after application of TRPA1 agonists such as
CIN and allyl isothyocyanate (AITC) has been shown already
before14-16, due to an increase of 5-hydroxytryptamine (5-HT)
released. The authors could also show high expression of TRPA1
mRNA by ISH in enterochromaffin cells secreting 5-HT in the small
intestine. A more recent study describes the expression of TRPA1
mostly in the myenteric ganglia on the stomach and in the myenteric
and submucosal ganglia of the small and large intestine32 with a low
level of expression in epithelial cells of the small intestine and colon.
Surprisingly, the authors specified that TRPA1 immunoreactivity
was not concentrated in discrete populations of epithelial cells such
as EC32 and no effect of AITC by gavage in gastric emptying and
small intestinal transit has been observed.
In the present study, CIN induced reduction of gastric emptying
correlates with a reduction of FI 2 hours after gavage. The high
expression of TRPA1 found in the stomach, the co-localization of
Figure 8 | Effect of chronic intake of 0.2% CIN included in the diet of obese mice on blood glucose after a gavage with glucose. After 5 weeks of
consumption of high fat diet containing 0.2%of CIN, an oral glucose tolerance test (OGTT)was performed by gavaging the animal with 2 g/kg bw of 20%
D-glucose in water. Glucose was assessed with a glucometer before and 15, 30, 60, and 120 min after glucose administration. Blood glucose levels are
significantly lower for CIN treated animals as compared to the controls for each time point before and after glucose gavage. (*, p,0.05; **, p,0.01; n512;
error bars: SEM).
Table 2 | Summary of significant differences observed in gene expression between mice treated (HFD 1 0,2%CIN) or not (HFD) with CIN.
(WAT: white adipose tissue; BAT: brown adipose tissue)
Relative mRNA amount to SDHA
TISSUE GENES HFD HFD 1 0.2% CIN t-test P-value N
BAT Acsl 4 0.012 6 0.0004 0.014 6 0.0006 0.015 10
WAT GLUT1 (Slc2a1) 0.146 6 0.012 0.210 6 0.0007 0.031 10
WAT GLUT12 (Slc2a12) 0.004 6 0.0002 0.006 6 0.0003 0.001 10
WAT GLUT8 (Slc2a8) 0.174 6 0.007 0.213 6 0.01 0.012 10
WAT Cpt1a 0.293 6 0.026 0.397 6 0.027 0.020 10
WAT Insulin receptor 0.286 6 0.019 0.368 6 0.026 0.029 10
www.nature.com/scientificreports
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TRPA1 with ghrelin in the small intestine and, the high in vitro
expression of TRPA1 in ghrelin secreting cells (MGN 3-1) with the
decrease in ghrelin secretion partially through TRPA1 activation,
allows us to explain the effect of the TRPA1 agonist in gastric emp-
tying and FI through a regulation of ghrelin secretion. It is well
known that ghrelin hormone stimulates gastric emptying and hun-
ger, even in humans33. Therefore, based on all data collected here
there is enough evidence to support that ghrelin secretion could be
reduced through TRPA1 activation. The activation of ghrelin secre-
tion through other tastants, more specifically different bitter tastants,
has been already shown34. Janssen et al. have shown that several T2R
agonists accelerated gastric emptying and that ghrelin localizes with
G proteins of the gustatory complex (alpha-gustducin and alpha-
transducin) in EC cells. Taken together these results open a new
potential approach to investigate how sensory stimuli regulate endo-
genous release of ghrelin for therapeutic intervention.
After 23 days ofHFD supplemented with 0.2% of CIN a significant
decrease in cumulative body weight gain is observed without a
decrease in daily food intake during the entire study. The NMR
results collected at the end of the treatment indicate a tendency to
reduce fat mass. To date, two theories could explain CIN effects on
body weight and on adipose tissue. The first one proposes that
TRPA1 activation increases thermogenesis via the b-adrenergic
pathway19. However, in our study no differences in the plasma cate-
cholamine levels are detected. The second explanation proposed in
the literature is that CIN prevents adipocyte differentiation and adi-
pogenesis, based on the in vitro results obtained with 3T3-1L via
down-regulating PPARc and up-regulating AMPK pathways35.
The authors also found an improvement of insulin secretion and
fasting glucose plasma levels, together with a decrease in triglycerides
(TG), non-esterified fatty acids (NEFA) and cholesterol serum levels.
In our study, not only a decreased glucose level is observed in fasting
condition but also after a glucose gastric load in CIN-treated mice.
Tamura et al.21, also found a decrease in adipose tissue as we did, but
they explained it by an activation of UCP1 BAT. The reduction of fat
mass we observed suggests also an increase of cellular metabolism;
however, in our study we do not observe a difference in UCP activity
(UCP1, 2 and 3). Nonetheless this hypothesis is supported by the up-
regulation we observe of ACSL4 (in BAT) and Cpt1a (in WAT),
which could indicate an increase of fatty acid oxidation36.
On the other hand, it is known that CIN is easily oxidized into
cinnamic acid (CNA)37. This data brings up the possibility that the
long-term effects we observe in our study are due to CNA instead of
CIN but as hTRPA1 transfected cells were not activated by CNA
(data not shown), the effects described during the chronic treatment
cannot be due to TRPA1 activation by CNA. However, a different
pathway could be involved in this decrease of fat mass as Kopp S.P. et
al., 201438 recently described. They showed an increase of adiponec-
tin and pAMPK/AMPK ratio through GPR109A activation by CNA
in 3T3-L1 adipocytes.
Other TRP channels have also been associated to thermogenesis of
BAT. It has been shown that mice receiving a chronic treatment with
menthol, as a TRPM8 agonist, showed an increase of the core tem-
perature and locomotor activity, plus elevated levels of UCP-1 in
brown adipocytes (in vitro)39.
Taken together, we conclude that the TRPA1 pathway is a poten-
tial target to improve cellular metabolism, insulin sensitivity, and to
reduce fat mass.
Methods
Animals. C57BL6/J mice were obtained from Charles River (France), C57BL/6NTac
Mice onHigh Fat Diet (DIO-B6) from Taconic (Denmark) and TRPA1 KO (trpa1 -/-)
(B6; 129P-Trpa1tm1kykw/J) from The Jackson Laboratory. Mice were maintained as
heterozygotes, and age- and sex-matched littermates were studied. Mice were
maintained at 22uC with a 12h dark-12h light cycle.
All procedures were conducted in conformity with the Swiss Welfare Act and the
Swiss National Institutional Guidelines on Animal Experimentation for the ethical
use of animals. The project was approved by an Internal Experimentation Ethics
Committee and the Swiss Cantonal Veterinary Office following its ethical review by
the State Committee for Animal Experimentation.
Acute condition of treatment with Cinnamaldehyde.Dose of Cinnamaldehyde:The
dose of 250 mg/kg/day of cinnamaldehyde was chosen based on the acceptable daily
consumption (ADI) of 1.25 mg/kg of body weight40. A safety factor of 200 was
adopted. allows for differences between test species and human beings (10 times) and
differences between individuals (10 times)41.
Food intake measurements: To measure the impact of a single dose of CIN on food
intake, single housed C57BL6 mice, fasted during 23 hours, received a gavage of
250 mg/kg bw of CIN and food intake was measured every two hours during the
following 24 hours, starting at the beginning of the dark cycle. Mice were housed
during themeasurementwithout litter. A plate with a single pellet was placed in a cage
and was weighed every 2 hours together with the food waste that was found in the
bottom of the cage.
Gastric emptying and gastrointestinal transit time was measured after 18 h over-
night fast. FITC-labeled dextran (70,000 MW; Molecular Probes) was administered
by gavage (100 ml of a 5-mg/ml solution prepared in water). Sixty minutes later, the
entire GI tract from stomach to rectum was removed and placed in ice for 30 s to
inhibit motility. The stomach, small intestine (divided into 10 equal length segments),
cecum, and colon (subdivided into two equal-length segments) were each placed in a
separate tube containing PBS. The segments were coarsely chopped with scissors, and
luminal contents suspended using a combination of vigorous washing and vortexing.
The fluorescent signal was quantified in a multiwell fluorescence plate reader
(Flexstation II fluorescent plate reader; excitation at 485 nm; emission at 530 nm;
Molecular Devices). The geometric center was determined as: (SUM [% of total
fluorescence per segment 3 segment number])/100)42. Gastric emptying was calcu-
lated based on the amount of FITC-dextran left in the stomach compared with the
total amount of fluorescence in the gastrointestinal tract.
Long term treatment with CIN included in the diet. Dose of Cinnamaldehyde: The
dose of 0.2%CIN is based on the same daily consumption used for the acute treatment
(250 mg/kg bw) assuming a minimal body weight of 25 gr/mice and a daily food
intake of 3 gr.
Sixty mice were fed with a high fat diet (HFD) containing 60% of the calories as fat
(D12492, Research Diet) for 10 weeks. The mice became obese (min. 40 g bw) and
were randomized in two groups. The control group was fed with HFD and the group
‘‘treatedwithCIN’’ was fedwithHFD ad libitum supplementedwith 0.2% ofCIN over
the following 36 days. Food intake and body weight gain were recorded daily, and
glucose tolerance was assessed at the end of the treatment. At the end of the experi-
ment themice were sacrificed after a 6-h fasting period; blood and tissue samples were
collected and stored at 280uC for further analyses as detailed below.
Histology (Tissue preparation immunohistochemistry/In situ hybridization
(IHC/ISH)). Mice were anesthetized and intracardiacally perfused with a saline
solution to remove blood from the vessels and small capillaries followed by a
perfusion of 4% paraformaldehyde (PFA) in PBS. Different tissue samples were
collected to perform in-situ hybridization and immune-staining. The tissue was
rinsed with PBS and immersed in 4% PFA in PBS overnight at 4uC, cryoprotected in a
solution of 20% sucrose in PBS and embedded in Tissue-Tek optimal cutting
temperature compound (Sakura) frozen in dry ice. Sections of 16 mmwere cut in the
cryostat for ISH/IHC.
In Situ Hybridization (ISH): Sections were fixed in 4%PFA in PBS for 10 minutes
and washed in PBS. The sections were then treated with Proteinase K solution (10 ng/
mg in 100 nM Tris-HCl (pH 8), 50 mM EDTA for 5 minutes at 37uC and acetylated
as follows: washed in PBS for 1minute, 2minutes in 100 mM triethanolamine (pH 8),
10 min with 0.25% acetic anhydride in 100 mM triethanolamine (pH 8), and finally
washed with PBS for 1 minute and air dried. Afterward, the hybridization solution
(50% formamide, 600 mM NaCl, 10 mM tris-HCl (pH 8), 1 mM EDTA, 1X
Denhardt’s solution, 0.25% SDS, 10% dextran sulfate, 200 ug/ml yeast RNA) was
applied at 85uC for 10 minutes and finally digoxigenin-labeled probes for TRPA1
were added to in the solution pre-heated at 85uC for 3minutes. The hybridization was
done at 60uC overnight in a humidified chamber containing 50% formamide.
The following day sections were washed in 2xSSC containing 50% formamide at
60uC for 30 minutes, twice in 2xSSC at 60uC for 20 minutes and twice in 0.2xSSC at
60uC for 20 minutes.
Immunohistochemistry (TSA biotin system IHC). First, to quench endogenous
peroxidase activity, a solution of 0.3% H2O2 was applied in PBS for 30 minutes and
slides were blocked in TNB blocking buffer (0.1 M Tris-HCl, pH 7.5, 0.15 M NaCl,
0.5% Blocking Reagent) at room temperature (RT).
In a next step, slides were incubated with horse-radish peroxidase-conjugated
antibody, anti-DIG-POD (15100) at room temperature for 30 minutes and slides
were washed in PBS.
Slides were then incubated in Biotinyl Tyramide amplification reagent and
thereafter washed again. Following, incubation in streptavidin-Alexa Fluor 488 (SA-
488; Invitrogen) (15100) during 30 minutes at RT. Sections were blocked in blocking
buffer for 1 hour at RT and the primary anti- ghrelin antibody (sc-10368; Santa Cruz
Biotechnology) was added (151000) in the blocking buffer overnight at 4uC. To finish,
the slides were incubated with a secondary antibody anti-goat alexa 555 (151000;
Invitrogen).
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Ghrelin secretion in MGN3-1 cells: measurements in culture media and gene
expression analysis. MGN 3-1 cells were grown as indicated by Iwakura H. et al.,
2010, in DMEM (41966-029; Life technologies) supplemented with 10% FBS, 100 U/
ml penicillin, and 100 g/ml streptomycin at 37uC in 10% CO2. MGN3-1 cells were
seeded and cultured overnight in 12-well microtiter plates (7.5 3 105 cells/well).
Subsequently, cells were incubated at 37uC for 4 h in DMEM supplemented with
0.5%BSA, as previously described by IwakuraH. et al., 2010, andwith or without CIN
before collecting supernatants. To measure ghrelin the culture medium was
centrifuged, and the resulting supernatants were immediately applied to Sep-Pak C18
cartridges (Waters Corp.) pre-equilibrated with 0.9% saline. Cartridges were washed
in saline and 5%CH3CN/0.1% trifluoroacetic acid and eluted with 60%CH3CN/0.1%
trifluoroacetic acid. Ghrelin concentrations in the supernatant were measured by
ELISA (kit EZRGRA-90K, Millipore).
To determine the expression levels of ghrelin (taqman primers:
Mm00445450_m1), GOAT(Mm01200389_m1), InsR (Mm01211875_m1) and
TRPA1 (Mm01227437) mRNA, cells were incubated at 37uC for 24 h in DMEM
supplemented with 0.5% BSA and the indicated additional reagents. Total RNA was
extracted using a RNeasy Micro Kit (Qiagen). Reverse transcription was performed
with a high-capacity RNA-to-cDNA kit (Applied Biosystems). Real-time quantitative
PCR was performed using an ABI PRISM 7900HT sequence detection system
(Applied Biosystems) using appropriate primers and TaqMan probes
(Supplementary information table 1). The mRNA expression of each gene was nor-
malized to levels of b-actin.
Oral glucose tolerance test.Mice were fasted for six hours during the light cycle and
the fasting glycemia baseline was measured with a glucose meter (Ascensia Elite XL,
Bayer). Then, a gavage containing a 30% glucose solution (D-Glucose 2 mg/g BW)
was carried out and several blood samples were collected 159, 309, 609 and 1209 after
glucose load. Blood collections for insulin measurements are only at time points
09,159 and 609. Insulin levels weremeasured according to the provided protocol of the
company (90060:96test; Chrystal Chem).
Measurement of body fatmass and leanmass.Body compositionwas determined, at
day 0 and at the end of treatment, by nuclear magnetic resonance (NMR) using Echo
MRI TM (Echo Medical Systems).
Biochemical blood assays. Blood levels of aspartate transaminase (AST) (#04657543
190;Roche), and alanine aminotransferase (ALT) (#04718569 190; Roche,), creatinine
(#05401755 190; Roche,), total cholesterol (#04718917 190; Roche), triglycerides
(#04657594 190; Roche,), free fatty acids (#434-91795, 436-91995; WAKO) were
measured using the Cobas c111 spectrophotometer (Roche Diagnostic GmbH).
Plasma levels of adrenaline, noradrenaline and dopamine plasma levels were assayed
by ELISA followingmanufacturer’s instructions (BA E-5100: Adrenaline; BA E-5200:
Noradrenaline; BA E-5300: Dopamine (Labor Diagnostika Nord, GmbH & Co.KG).
Fecal Calorie content. At the end of the treatment, over 24 hours, mouse feces were
collected and were frozen at -80uC. The feces were dried by vacuum oven-drying
(50uC, 24 hours). Dried feces were then homogenized with a mortar, and compacted
into two pellets using a Pellet Press 2811 (Parr Instrument Company). The dried
materials were added to 0.4 g benzoic acid and burned in a 6100 Oxygen Bomb
Calorimeter (Parr Instrument Company) to measure their caloric content.
Measurements were done in duplicate.
Gene Expression Analysis. Tissue was collected at the end of the treatment. 10 mice
per group were euthanized and samples of inguinal white adipose tissue and
interscapular brown adipose tissue, muscle from quadriceps and liver were dissected
and frozen immediately in liquid nitrogen.
Gene expression analysis: changes in gene expression were measured by qRT-PCR
in dissected tissue. Samples were homogenized using Lysing Matrix D tubes (MPbio)
and total RNA was extracted using the Agencourt RNAdvance Tissue system. The
mRNA expression of each gene was normalized to levels of beta-actin. cDNA was
synthesized using the High Capacity RNA-to-cDNA Kit (Applied Biosystems) and
Real-time PCR was performed using an ABI PRISM 7900 HT Sequence Detection
System (Applied Biosystems). The expression levels of the different genes and two
different reference genes were measured with pre-designed Taqman gene expression
assays, each containing two gene specific primers and an internal FAMTM dye-labeled
TaqManHMGB probe. See taqman probes used for the different tissues in supple-
mentary information table 1.
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